Company: DRTSW
Filing Date: 2025-03-12
Form Type: 20-F
Source: 0001213900-25-023187
Chunk: 121

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-03-12
Form: 20-F
Item: Item 4
Chunk 121
---
 bone
metastases associated with prostate cancer. Other experimental systemic alpha applications often rely on the conjugation of an
alpha-emitting radioisotope with a targeting mechanism such as an antibody (creating an antibody-radionuclide conjugate), with the
aim of preferential attachment to cancer cells throughout the body before the radionuclide decays. No solution has been approved
that delivers local alpha particles able to penetrate into the depth of tumors, which we believe has hindered the local
radiotherapeutic utility of alpha emitters.

Our Solution: Alpha DaRT® Technology

Mechanism of Action of the Alpha DaRT ®

The Alpha DaRT technology
is designed to act through the controlled release of alpha-emitting atoms directly into a tumor, relying on the innate decay chain of
Radium-224 to release and propel multiple alpha emitters deeper into the tumor than can be achieved by the limited (less than 100 μm)
ranges of the alpha particles themselves. Radium-224, with a decay chain releasing four alpha particles, has a half-life of approximately
3.7 days, while the remaining decay chain has a total half-life of approximately 12 hours, before eventually stabilizing in inert form.

The Alpha DaRT utilizes stainless
steel or titanium sources that are embedded with Radium-224. The Alpha DaRT source is designed to be injected into the tumor using one
of the proprietary applicators we have developed. Once injected, the radium remains attached to the source, while its daughter atoms detach,
spontaneously decay and recoil in succession, with the goal of emitting potentially cytotoxic alpha particle payloads as they move deeper
into the tumor until eventually stabilizing. The sources are designed to be placed a few millimeters apart from each other in the tumor
to fully utilize the range of each source, and the Alpha DaRT’s localized action is designed to kill the cancer cells while sparing
the neighboring healthy cells.

The illustration below depicts
the decay chain process of Radium-224, which is affixed to the Alpha DaRT source while its daughter atoms are designed to diffuse inside
a tumor.

The graphics below illustrate
the radioactivity seen in a cross-section of a tumor grown in a mouse with a single Alpha DaRT source through the center, as well as the
impact on the tumor from an adjacent slice under a histological stain. As illustrated, the Alpha DaRT delivered a high dose of radiation
in a very conformal form, with near zero radiation detected outside